Physician profile
James Williams
NPI 1497753594
$3,186.70
in general payments reported to CMS, 2019-2025
13 companies · $896 in 2025
The $896 reported for 2025 was more than what 77% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $185 · 2020: $207 · 2021: $213 · 2022: $435 · 2023: $529 · 2024: $721 · 2025: $896.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,146.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $970.71 | 2020-2025 | Arikayce, Brinsupri |
| Gilead Sciences, INC. | $503.46 | 2021-2025 | |
| Mimedx Group, INC. | $503.08 | 2024-2025 | |
| Organogenesis INC. | $421.54 | 2024-2025 | Apligraf, Puraply Wound Matrix |
| Abbvie INC. | $310.36 | 2021-2025 | Dalvance, Teflaro |
| Viiv Healthcare Company | $226.01 | 2019-2021 | |
| Allergan, INC. | $126.18 | 2019 | |
| Travere Therapeutics, INC. | $29.87 | 2024 | |
| Melinta Therapeutics, LLC | $25.07 | 2019 | |
| Merck Sharp & Dohme LLC | $22.34 | 2024 | Winrevair |
| Bayer Healthcare Pharmaceuticals INC. | $17.76 | 2025 | |
| Integra Lifesciences Corporation | $17.61 | 2024 | Tcc-Ez |
| Kowa Pharmaceuticals America, INC. | $12.71 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.